XML 58 R46.htm IDEA: XBRL DOCUMENT v3.25.2
Equity Transactions - Additional Information (Details) - USD ($)
 2 Months Ended 12 Months Ended
Oct. 27, 2023
Oct. 06, 2023
Jul. 19, 2023
Apr. 20, 2023
Sep. 07, 2021
Nov. 01, 2019
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Apr. 15, 2024
Equity Transactions                    
Interest expense                 $ 49,808  
Common shares issued as compensation and for services               $ 162,625 $ 178,940  
Employees                    
Equity Transactions                    
Stock-based compensation expense               $ 2,125    
Shares granted               1,786 1,786  
Share-based payment arrangement, nonemployee                    
Equity Transactions                    
Common shares issued as compensation and for services                 $ 2,340  
ATM Offering                    
Equity Transactions                    
Aggregate offering price                   $ 50,000,000
Issuance of shares             1,308,651 3,351,096    
Average price             $ 2.47 $ 1.64 $ 2.47  
Net proceeds       $ 3,120,000       $ 5,296,000    
Warrants                    
Equity Transactions                    
Number of fully vested warrants granted to purchase shares of common stock               1,144 1,144  
Non-cash compensation expense recognized               $ 679 $ 563  
Warrants | Minimum                    
Equity Transactions                    
Exercise price (in dollars per share)             1.43 $ 1.55 $ 1.43  
Warrants | Maximum                    
Equity Transactions                    
Exercise price (in dollars per share)             $ 2.43 $ 2.35 $ 2.43  
Founder, Chairman and President                    
Equity Transactions                    
Employment agreement extension term (in years)   1 year           1 year    
TheraCour Pharma Inc | Related party                    
Equity Transactions                    
Number of shares upon principle of note convertible 331,859                  
Gain on extinguishment                 $ 49,808  
Issuance of shares           75,000        
TheraCour Pharma Inc | Related party | Unsecured promissory note                    
Equity Transactions                    
Interest rate per annum (as a percent)     12.00%              
Director                    
Equity Transactions                    
Stock-based compensation expense               $ 45,000 $ 45,000  
Number of shares authorized               30,746 33,579  
Consulting services                    
Equity Transactions                    
Stock-based compensation expense               $ 115,500 $ 131,600  
Number of shares authorized               79,149 101,542  
Common Stock                    
Equity Transactions                    
Issuance of shares               3,351,096 1,308,651  
Series A Preferred Stock | Employees                    
Equity Transactions                    
Shares granted                 2,888  
Series A Preferred Stock | Share-based payment arrangement, nonemployee                    
Equity Transactions                    
Common shares issued as compensation and for services               $ 10,809 $ 10,747  
Series A Preferred Stock | Founder, Chairman and President                    
Equity Transactions                    
Number of shares vest on quarterly installments   2,551           2,551    
Non-cash compensation expense                 $ 32,498  
Shares granted   10,204           10,204    
Series A Preferred Stock | TheraCour Pharma Inc                    
Equity Transactions                    
Number of shares upon principle of note convertible     331,859              
Debt instrument, conversion stock, par value     $ 0.00001              
Series A Preferred Stock | TheraCour Pharma Inc | Related party                    
Equity Transactions                    
Issuance of shares         50,000          
Series A Preferred Stock | Employee compensation | Employees                    
Equity Transactions                    
Shares granted               2,888    
Series A Preferred Stock | Founder, Chairman and President                    
Equity Transactions                    
Non-cash compensation expense               $ 49,834